section name header

Pronunciation

glye-koe-PYE-roe-late

Classifications

Therapeutic Classification: antispasmodics

Pharmacologic Classification: anticholinergics

Indications

REMS


Oral solution

Action

  • Inhibits the action of acetylcholine at postganglionic sites located in smooth muscle, secretory glands, and the CNS (antimuscarinic activity).
  • Low doses decrease sweating, salivation, and respiratory secretions.
  • Larger doses decrease GI and GU tract motility.
Therapeutic effects:
  • Decreased GI and respiratory secretions.

Pharmacokinetics

Absorption: Incompletely absorbed (<10%) after oral administration. Well absorbed after IM administration. IV administration results in complete bioavailability.

Distribution: Distribution not fully known. Does not significantly cross the blood-brain barrier or eye.

Metabolism/Excretion: Eliminated primarily unchanged in the urine and bile.

Half-Life: 1.7 hr (0.6–4.6 hr).

Time/Action Profile

(anticholinergic effects)

ROUTEONSETPEAKDURATION
PO1 hrunknown8–12 hr
IM15–30 min30–45 min2–7 hr*
IV1–10 minunknown2–7 hr*



*Antisecretory effect lasts up to 7 hr; vagal blockade lasts 2–3 hr.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: tachycardia, orthostatic hypotension, palpitations

Derm: flushing

EENT: nasal congestion, blurred vision, cycloplegia, dry eyes, mydriasis

GI: dry mouth, vomiting, constipation

GU: urinary hesitancy, urinary retention

Neuro: headache, confusion, drowsiness.

Interactions

Drug-drug:

Route/Dosage

Control of Secretions during Surgery

Control of Secretions (chronic)

Cholinergic Adjunct

Peptic Ulcer

Chronic Severe Drooling

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Cuvposa, Glycate, Glyrx-PF, Robinul, Robinul Forte